To support development of new potency assays and process analytical technologies
Medicago, a Canadian biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), has been awarded up to US$493,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
The investment will support the development of new potency assays and process analytical technologies for Medicago's pandemic and seasonal influenza VLP vaccine candidates.
‘The development of the best assays that can ensure rapid release and availability of our influenza vaccine candidates aligns well with our strategy to deliver highly effective vaccines in the quickest possible manner,’ said Andy Sheldon, president and CEO of Medicago.
‘This contribution continues to demonstrate our long-standing relationship with NRC IRAP. We would sincerely like to thank them for their continued support and encouragement of Medicago.’
Medicago will work with NRC teams in Montreal and Ottawa to establish assays for more rapid lot release and better in-process control.